324 related articles for article (PubMed ID: 12566519)
41. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
[TBL] [Abstract][Full Text] [Related]
42. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree.
Sainio M; Strachan T; Blomstedt G; Salonen O; Setälä K; Palotie A; Palo J; Pyykkö I; Peltonen L; Jääskeläinen J
Neurology; 1995 Jul; 45(7):1314-22. PubMed ID: 7617190
[TBL] [Abstract][Full Text] [Related]
43. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.
Evans DG; Ramsden RT; Shenton A; Gokhale C; Bowers NL; Huson SM; Pichert G; Wallace A
J Med Genet; 2007 Jul; 44(7):424-8. PubMed ID: 17307835
[TBL] [Abstract][Full Text] [Related]
44. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.
Bijlsma EK; Wallace AJ; Evans DG
J Med Genet; 1997 Nov; 34(11):934-6. PubMed ID: 9391890
[TBL] [Abstract][Full Text] [Related]
45. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.
Baser ME;
Hum Mutat; 2006 Apr; 27(4):297-306. PubMed ID: 16521120
[TBL] [Abstract][Full Text] [Related]
46. A point mutation associated with a severe phenotype of neurofibromatosis 2.
MacCollin M; Braverman N; Viskochil D; Ruttledge M; Davis K; Ojemann R; Gusella J; Parry DM
Ann Neurol; 1996 Sep; 40(3):440-5. PubMed ID: 8797533
[TBL] [Abstract][Full Text] [Related]
47. [Type 2 neurofibromatosis without acoustic neuroma].
Mautner VF; Lindenau M; Köppen J; Hazim W; Kluwe L
Zentralbl Neurochir; 1995; 56(2):83-7. PubMed ID: 7639047
[TBL] [Abstract][Full Text] [Related]
48. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
49. Allelic status of 1p, 14q, and 22q and NF2 gene mutations in sporadic schwannomas.
Leone PE; Bello MJ; Mendiola M; Kusak ME; De Campos JM; Vaquero J; Sarasa JL; Pestana A; Rey JA
Int J Mol Med; 1998 May; 1(5):889-92. PubMed ID: 9852312
[TBL] [Abstract][Full Text] [Related]
50. Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager.
Gripp KW; Baker L; Kandula V; Piatt J; Walter A; Chen Z; Messiaen L
Clin Genet; 2017 Nov; 92(5):540-543. PubMed ID: 28295212
[TBL] [Abstract][Full Text] [Related]
51. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG
J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874
[TBL] [Abstract][Full Text] [Related]
52. Neurofibromatosis type 2 in the elderly population: clinical and molecular features.
Goutagny S; Bah AB; Parfait B; Sterkers O; Kalamarides M
Am J Med Genet A; 2013 Apr; 161A(4):667-70. PubMed ID: 23322716
[TBL] [Abstract][Full Text] [Related]
53. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.
Mautner VF; Baser ME; Thakkar SD; Feigen UM; Friedman JM; Kluwe L
J Neurosurg; 2002 Feb; 96(2):223-8. PubMed ID: 11838794
[TBL] [Abstract][Full Text] [Related]
54. Sporadic vestibular schwannoma: a molecular testing summary.
Sadler KV; Bowers NL; Hartley C; Smith PT; Tobi S; Wallace AJ; King A; Lloyd SKW; Rutherford S; Pathmanaban ON; Hammerbeck-Ward C; Freeman S; Stapleton E; Taylor A; Shaw A; Halliday D; Smith MJ; Evans DG
J Med Genet; 2021 Apr; 58(4):227-233. PubMed ID: 32576656
[TBL] [Abstract][Full Text] [Related]
55. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.
Wallace AJ; Watson CJ; Oward E; Evans DG; Elles RG
Genet Test; 2004; 8(4):368-80. PubMed ID: 15684865
[TBL] [Abstract][Full Text] [Related]
56. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
57. Neurofibromatosis type 2.
Uppal S; Coatesworth AP
Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
[TBL] [Abstract][Full Text] [Related]
58. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas.
Hung G; Faudoa R; Baser ME; Xue Z; Kluwe L; Slattery W; Brackman D; Lim D
Cancer Genet Cytogenet; 2000 Apr; 118(2):167-8. PubMed ID: 10748301
[TBL] [Abstract][Full Text] [Related]
59. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.
Sainio M; Jääskeläinen J; Pihlaja H; Carpén O
Neurology; 2000 Mar; 54(5):1132-8. PubMed ID: 10720287
[TBL] [Abstract][Full Text] [Related]
60. [Neurofibromatosis type 2 (NF2)].
Araki N; Takeshima H; Saya H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
